Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fractyl Health (GUTS) Cash & Equivalents (2023 - 2025)

Fractyl Health's Cash & Equivalents history spans 3 years, with the latest figure at $81.5 million for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents rose 20.86% year-over-year to $81.5 million, compared with a TTM value of $81.5 million through Dec 2025, up 20.86%, and an annual FY2025 reading of $81.5 million, up 20.86% over the prior year.
  • Cash & Equivalents for Q4 2025 was $81.5 million at Fractyl Health, up from $77.7 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $121.4 million in Q1 2024, with the low at $22.3 million in Q2 2025.
  • Average Cash & Equivalents over 3 years is $70.3 million, with a median of $77.7 million recorded in 2025.
  • Year-over-year, Cash & Equivalents soared 103.15% in 2024 and then crashed 78.23% in 2025.
  • Tracing GUTS's Cash & Equivalents over 3 years: stood at $33.2 million in 2023, then skyrocketed by 103.15% to $67.5 million in 2024, then increased by 20.86% to $81.5 million in 2025.
  • Per Business Quant, the three most recent readings for GUTS's Cash & Equivalents are $81.5 million (Q4 2025), $77.7 million (Q3 2025), and $22.3 million (Q2 2025).